| 标题： | 中国女性乳腺癌患者化疗期间乙肝病毒及丙肝病毒再激活管理专家共识 |
| title： | Chinese expert consensus recommendations for management of Hepatitis B and C Virus reactivation in Chinese female patients with breast cancer during chemotherapy |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 中国乳腺疾病专业临床医生 |
| Guide users： | Clinicians specializing in breast diseases in China |
| 证据分级方法： | GRADE分级系统并结合国内临床研究和专家临床经验 |
| Evidence grading method： | The evidence grading system was developed by incorporating elements of the GRADE system along with insights gleaned from clinical studies conducted in China and expert clinical experience. |
| 制定单位： | 中国抗癌协会乳腺肿瘤整合康复专业委员会、国家肿瘤质控中心乳腺癌专家委员会、中国医师协会外科医师分会乳腺外科专家工作组、中国抗癌协会肿瘤临床研究管理学专业委员会、重庆市临床医学研究联合会和重庆抗癌协会肿瘤内分泌专业委员会 |
| Formulating unit： | the Society of Breast Cancer Integration and Rehabilitation of China Anti-Cancer Association, Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Surgery Expert Working Group of the Surgeons' Branch of the Chinese Medical Doctor Association, the Society of Clinical Cancer Research Administration of China Anti-Cancer Association, Chongqing Federation of Clinical Medical Research, the Society of Onco-endocrinology of Chongqing Anti-Cancer Association |
| 注册时间： | 2024-06-12 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN793 |
| Registration number： | |
| 指南制订的目的： | 乙肝病毒感染是一个全球性的健康问题，中国作为乙肝病毒的中高流行区域，同时丙型肝炎病毒的感染基数也不容忽视。乳腺癌患者常采用化疗作为治疗手段，但慢性肝炎病毒感染者在接受化疗期间存在病毒再激活的风险。乙肝病毒和丙肝病毒的再激活不仅可能导致患者血清中的氨基转移酶水平升高，还可能引发暴发性肝炎、急性肝衰竭等严重并发症，甚至导致化疗中断和患者死亡，这将严重影响患者的肿瘤治疗进程和预后。因此，正确认识乳腺癌患者化疗期间乙肝病毒及丙肝病毒再激活，制定规范的防治措施，对改善患者生活质量及预后具有重要意义。为此，专家组成员结合最新相关文献和多个中心的临床经验，进行针对性讨论，撰写了《中国女性乳腺癌患者化疗期间乙肝病毒及丙肝病毒再激活管理专家共识》，旨在为我国女性乳腺癌患者化疗期间的乙肝病毒及丙肝病毒再激活的规范化管理提供参考，以进一步提高乳腺癌患者的生活质量并改善预后。 |
| Purpose of the guideline： | Hepatitis B virus (HBV) infection is a pervasive global health challenge, with China classified as a region of moderate to high endemicity for HBV. Concurrently, the prevalence of hepatitis C virus (HCV) infection warrants significant attention. Chemotherapy is a common therapeutic modality for breast cancer patients; however, individuals with chronic hepatitis viral infections are at an elevated risk of viral reactivation during chemotherapy. Reactivation of HBV and HCV can lead to a significant rise in serum aminotransferase levels and may precipitate severe complications such as fulminant hepatitis and acute hepatic failure. These complications can result in the discontinuation of chemotherapy and, in the most severe cases, patient mortality, thereby adversely impacting the oncological treatment process and prognosis. Appreciating the complexities of HBV and HCV reactivation during chemotherapy for breast cancer is crucial for the development of standardized prophylactic and therapeutic interventions aimed at enhancing patient quality of life and improving clinical outcomes. In light of this, a panel of experts, drawing upon the latest literature and clinical insights from multiple centers, has engaged in focused deliberations and authored the " Chinese expert consensus recommendations for management of Hepatitis B and C Virus reactivation in Chinese female patients with breast cancer during chemotherapy" This consensus document is intended to serve as a reference for the standardized management of HBV and HCV reactivation in this patient population, with the goal of augmenting the quality of life and clinical prognosis for breast cancer patients. |
